用于治疗癌症的新型CD73抑制剂
Novel CD73 Inhibitors for Treating Cancer.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Apr 9;15(5):571-572. doi: 10.1021/acsmedchemlett.4c00137. eCollection 2024 May 9.
Abstract
Provided herein are novel CD73 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
摘要
本文提供了新型CD73抑制剂、药物组合物、此类化合物在治疗癌症中的用途以及制备此类化合物的方法。
相似文献
1
Novel CD73 Inhibitors for Treating Cancer.用于治疗癌症的新型CD73抑制剂
ACS Med Chem Lett. 2024 Apr 9;15(5):571-572. doi: 10.1021/acsmedchemlett.4c00137. eCollection 2024 May 9.
2
Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer.新型杂芳基化合物作为用于治疗癌症的CD73抑制剂
ACS Med Chem Lett. 2024 May 31;15(6):775-776. doi: 10.1021/acsmedchemlett.4c00230. eCollection 2024 Jun 13.
3
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.作为用于治疗癌症的CD73抑制剂的新型双环杂环化合物。
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
4
Novel Compounds as TEAD Inhibitors for Treating Cancer.用于治疗癌症的新型TEAD抑制剂化合物
ACS Med Chem Lett. 2023 Aug 22;14(9):1152-1153. doi: 10.1021/acsmedchemlett.3c00346. eCollection 2023 Sep 14.
5
Novel Compounds as CDK2 Inhibitors for Treating Cancer.新型化合物作为治疗癌症的CDK2抑制剂
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
6
Novel Quinoline Compounds as KRAS Inhibitors for Treating Cancer.新型喹啉化合物作为治疗癌症的KRAS抑制剂
ACS Med Chem Lett. 2023 May 26;14(6):707-708. doi: 10.1021/acsmedchemlett.3c00195. eCollection 2023 Jun 8.
7
Novel 2,7-Naphthyridine Compounds as MASTL Inhibitors for Treating Cancer.新型2,7-萘啶化合物作为治疗癌症的MASTL抑制剂
ACS Med Chem Lett. 2024 May 1;15(6):748-749. doi: 10.1021/acsmedchemlett.4c00177. eCollection 2024 Jun 13.
8
Novel Pyrazoloquinoline Compounds as KRAS Inhibitors for Treating Cancer.新型吡唑并喹啉化合物作为治疗癌症的KRAS抑制剂
ACS Med Chem Lett. 2023 Jul 25;14(8):1045-1046. doi: 10.1021/acsmedchemlett.3c00300. eCollection 2023 Aug 10.
9
Novel Indazole Compounds as TEAD Inhibitors for Treating Cancer.新型吲唑化合物作为治疗癌症的TEAD抑制剂
ACS Med Chem Lett. 2023 Sep 20;14(10):1334-1335. doi: 10.1021/acsmedchemlett.3c00392. eCollection 2023 Oct 12.
10
Novel Tricyclic Compounds as KRAS Inhibitors for Treating Cancer.新型三环化合物作为治疗癌症的KRAS抑制剂
ACS Med Chem Lett. 2023 Apr 26;14(5):555-556. doi: 10.1021/acsmedchemlett.3c00140. eCollection 2023 May 11.
本文引用的文献
1
Metabolic interplay: tumor macrophages and regulatory T cells.代谢相互作用：肿瘤巨噬细胞和调节性 T 细胞。
Trends Cancer. 2024 Mar;10(3):242-255. doi: 10.1016/j.trecan.2023.11.007. Epub 2023 Dec 22.
2
Small molecular CD73 inhibitors: Recent progress and future perspectives.小分子 CD73 抑制剂：最新进展与未来展望。
Eur J Med Chem. 2024 Jan 15;264:116028. doi: 10.1016/j.ejmech.2023.116028. Epub 2023 Dec 7.
3
Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy.嵌合抗原受体自然杀伤细胞：一种有前景的抗肿瘤免疫疗法。
MedComm (2020). 2023 Dec 1;4(6):e422. doi: 10.1002/mco2.422. eCollection 2023 Dec.
4
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.CD38 抗体的免疫调节特性及其对多发性骨髓瘤抗癌疗效的影响。
Cancer Med. 2023 Oct;12(20):20332-20352. doi: 10.1002/cam4.6619. Epub 2023 Oct 15.
5
Advances in CD73 inhibitors for immunotherapy: Antibodies, synthetic small molecule compounds, and natural compounds.CD73 抑制剂在免疫治疗中的进展：抗体、合成小分子化合物和天然化合物。
Eur J Med Chem. 2023 Oct 5;258:115546. doi: 10.1016/j.ejmech.2023.115546. Epub 2023 Jun 5.
6
CD73 in glioblastoma: Where are we now and what are the future directions?胶质母细胞瘤中的 CD73：我们现在在哪里，未来的方向是什么？
Immunol Lett. 2023 Apr-May;256-257:20-27. doi: 10.1016/j.imlet.2023.03.005. Epub 2023 Mar 21.
Zotero 插件